Full-Time

Senior Manager Patient Services Operations

Patient Services Operations

Immunome

Immunome

201-500 employees

Antibody-based therapeutic discovery and development

Compensation Overview

$161.4k - $195.3k/yr

Bothell, WA, USA

In Person

Category
Medical, Clinical & Veterinary (1)

Get referred to Immunome

Find people who can refer or advise you

Requirements
  • Bachelor’s degree is required.
  • A minimum of 4 years of experience in the pharmaceutical or biotech industry, or equivalent experience.
  • A minimum of 2 years of experience in patient services operations, or equivalent experience.
Responsibilities
  • Support the translation of PSP strategy into operational requirements and implementation activities.
  • Participate in RFP development, vendor evaluation, and vendor onboarding activities with cross-functional partners.
  • Assist in managing vendor deliverables, timelines, and operational readiness activities.
  • Support implementation of key PSP services, including enrollment/intake, benefits verification, prior authorization support, financial assistance pathways, specialty pharmacy coordination, and adherence/persistence support.
  • Collaborate with Marketing to support development of patient and HCP materials, communication scripts, and educational resources.
  • Assist with development and deployment of operational training materials for field teams in partnership with Sales Training, Marketing, and Compliance.
  • Support day-to-day management of hub and PSP vendor operations.
  • Participate in regular operational meetings, issue tracking, and performance reviews.
  • Monitor operational metrics, dashboards, and SLA performance.
  • Help coordinate issue escalation and follow-up activities to support operational excellence.
  • Support adherence/persistence workflows and reporting activities in partnership with vendors and internal stakeholders.
  • Support maintenance of PSP SOPs, process documentation, and audit readiness materials.
  • Partner with Legal, Compliance, Regulatory, and PV/Safety teams to ensure operational processes align with company policies and reporting requirements.
  • Assist with quality assurance activities, documentation reviews, and process improvement initiatives.
  • Support operational reporting requirements and vendor data management activities.
  • Track launch readiness activities and post-launch operational KPIs.
  • Assist in monitoring patient journey metrics, including time-to-start, outreach effectiveness, and therapy access barriers, to identify operational improvement opportunities.
  • Prepare routine reporting summaries and operational updates for cross-functional stakeholders.
  • Collaborate closely with Market Access, Medical Affairs, Legal/Compliance, Regulatory, PV/Safety, Marketing, Finance, and Field teams.
  • Support coordination with Commercial Enablement and Distribution partners on operational integration activities.
  • Contribute to enterprise launch readiness initiatives and patient engagement priorities.
Desired Qualifications
  • Oncology experience preferred.
  • Advanced degree preferred.

Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Bothell, Washington

Founded

2008

Get referred to Immunome

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NDA filing for varegacestat creates near-term commercial revenue to fund ADC pipeline.
  • IND clearance and first dosing of IM-1617 in June 2026 validate undisclosed-target strategy.
  • Broad early-stage ADC portfolio against solid tumors supports multiple partnering opportunities.

What critics are saying

  • FDA rejection of varegacestat NDA within 6–12 months eliminates critical cash bridge funding.
  • Undisclosed RTK target validation failure in IM-1617 first-in-human trial kills the program.
  • Daiichi Sankyo and AstraZeneca dominate TOP1 ADC space, compressing Immunome's partnering leverage.

What makes Immunome unique

  • IM-1617 targets an undisclosed RTK driving both tumor survival and immune exclusion.
  • HC74 payload is a proprietary topoisomerase I inhibitor distinct from dominant DXd platforms.
  • Varegacestat offers an NDA-filed gamma secretase inhibitor with 84% progression risk reduction.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

21%

2 year growth

9%
Yahoo Finance
Apr 4th, 2026
Immunome CSO sells $204K in shares ahead of Q2 2026 NDA submission

Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.

Yahoo Finance
Mar 6th, 2026
Immunome cuts 2025 net loss to $212M, files $156M shelf registration ahead of varegacestat NDA

Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.

ChartMill
Jan 6th, 2026
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome to present at 44th Annual J.P. Morgan Healthcare Conference. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/

Business Wire
Dec 18th, 2025
Immunome Announces Pricing of Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today a...

Business Wire
Feb 1st, 2025
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies,